Thus far, one CTLA-4 inhibitor and several PD-1/PD-L1 inhibitors (Table 2) have been approved by the FDA for the clinical treatment of melanoma, lung cancer, HNSCC (Table 3), and other solid tumors. This evidence concerns the gene PDCD1 and melanoma.